The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours

References

• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–51–e551.
   Web of Science ®Google Scholar
• Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–256.
   PubMed Web of Science ®Google Scholar
• Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28(9):2107–2118.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
   PubMed Web of Science ®Google Scholar
• Bye A, Sjøblom B, Wentzel-Larsen T, et al. Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759–767.
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034–1041.
   PubMed Web of Science ®Google Scholar
• Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28(6):1054–1060.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006.
   PubMed Web of Science ®Google Scholar
• Argilés JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–762.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, et al. CANCER IMMUNOLOGY. The "cancer immunogram". Science. 2016;352(6286):658–660.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach toquantification of body composition in cancer patients using computed tomography images acquired during routine care. ApplPhysiolNutrMetabol. 2008;33:997–1006.
   Google Scholar
• Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–1547.
   PubMed Web of Science ®Google Scholar
• van der Werf A, Langius JAE, de van der Schueren MAE, et al. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. Eur J Clin Nutr. 2018;72(2):288–296.
   PubMed Web of Science ®Google Scholar
• Derstine BA, Holcombe SA, Ross BE, et al. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8(1):11369.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2019.
   Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and Neck. N Engl J Med. 2016;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–285.
   PubMed Web of Science ®Google Scholar
• Domblides C, Lartigue L, Faustin B. Control of the antitumor immune response by cancer metabolism. Cells. 2019;8(2):E104.
   PubMed Web of Science ®Google Scholar
• Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363–1372.
   PubMed Web of Science ®Google Scholar
• Metz R, Rust S, Duhadaway JB, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1(9):1460–1468.
   PubMed Web of Science ®Google Scholar
• Albiges L, Hakimi AA, Xie W, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 2016;34(30):3655–3663.
   PubMed Web of Science ®Google Scholar
• Ichihara E, Harada D, Inoue K, et al. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 2020;139:140–145.
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322.
   PubMed Web of Science ®Google Scholar
• Boi SK, Orlandella RM, Gibson JT, et al. Obesity diminishes response to PD-1-based immunotherapies in renal cancer. J Immunother Cancer. 2020;8(2):e000725.
   PubMed Web of Science ®Google Scholar
• Young AC, Quach HT, Song H, et al. Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA- 4 treatment in melanoma. J Immunother Cancer. 2020;8:e000821.
   PubMed Web of Science ®Google Scholar
• Roch B, Coffy A, Jean-Baptiste S, et al. Cachexia – sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020;143:19–26.
   PubMed Web of Science ®Google Scholar
• Khaki AR, Li A, Diamantopoulos LN, et al. Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020;126(6):1208–1216.
   PubMed Web of Science ®Google Scholar
• Prado CMM, Lima ISF, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67(1):93–101.
   PubMed Web of Science ®Google Scholar
• Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21(8):1594–1598.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLOS One. 2012;7(5):e37563.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–486.
   PubMed Web of Science ®Google Scholar
• Strulov Shachar S, Fried R, Shafran I, et al. Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (nivo). J Clin Oncol. 2018;36(15_Suppl):e21010–e21010.
   Web of Science ®Google Scholar
• Revel M-P, Raynard B, Pigneur F, et al. Sarcopenia and toxicity of the anti-PD1 inhibitors in real-life lung cancer patients: results from the French nationwide SCAN study. J Clin Oncol. 2018;36(15_Suppl):e21066–e21066.
   Web of Science ®Google Scholar
• Hirsch L, Bellesoeur A, Boudou-Rouquette P, et al. The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer. 2020;124:170–177.
   PubMed Web of Science ®Google Scholar
• Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.
   PubMed Web of Science ®Google Scholar